Search

for
Search:

GlossaryGoserelin

reduces sex hormone production to treat hormone-sensitive cancers

Goserelin, also known by the brand name Zoladex, is a type of medication called a gonadotropin-releasing hormone (GnRH) agonist. It is used to treat hormone-sensitive cancers such as prostate cancer in men and breast cancer in premenopausal women, as well as certain benign gynecological conditions like endometriosis. Goserelin works by reducing the production of sex hormones (testosterone and estrogen), which can help slow the growth of hormone-dependent tumors.

Related Terms

Sort by

Research

30 / 1000+ results

research An Open Randomized Comparative Study of an Oral Contraceptive Containing Ethinyl Estradiol and Cyproterone Acetate with and without the GnRH Analogue Goserelin in the Long-Term Treatment of Hirsutism

18 citations , March 2010 in “Gynecologic and obstetric investigation”

The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.

research Effect of the gonadotrophin releasing hormone analogue, goserelin, and oestradiol replacement on sebum excretion rates and hair size in mildly hirsute women

4 citations , January 1991 in “Journal of dermatological treatment”

Goserelin and oestradiol treatment slightly improved hairiness but did not significantly change sebum production or hair characteristics in mildly hirsute women.

research Enzalutamide/finasteride/goserelin/zoledronic-acid

July 2024 in “Reactions Weekly”

research Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient

9 citations , January 2018 in “Journal of the European Academy of Dermatology and Venereology”

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

research (PNM-35) Recurrent priapism in a sickle cell disease patient treated with gonadotropin-releasing hormone (GnRH) agonists drugs: a case report

February 2026 in “The Journal of Sexual Medicine”

GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.

research SUN-106 Nonsurgical Management of Hyperandrogenism in a Postmenopausal Woman

October 2025 in “Journal of the Endocrine Society”

Goserelin injections can effectively manage hyperandrogenism symptoms in postmenopausal women who can't have surgery.

research Slow progress in prostate cancer

February 2007 in “BJUI”

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

research Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin

36 citations , May 2011 in “The Journal of Clinical Endocrinology & Metabolism”

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

research DIAGNOSTIC AND THERAPEUTIC UTILITY OF GONADOTROPHIN-RELEASING HORMONE AGONIST IN POSTMENOPAUSAL HYPERANDROGENISM OF OVARIAN ORIGIN

July 2023 in “Journal of the ASEAN Federation of Endocrine Societies”

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

research Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism

3 citations , July 2009 in “Experimental and Clinical Endocrinology & Diabetes”

Low-dose Buserelin effectively reduces hirsutism with minimal side effects.

research Differential Suppression of Testosterone and Estradiol in Hirsute Women With the Superactive Gonadotropin-Releasing Hormone Agonist Leuprolide*

49 citations , October 1988 in “The Journal of Clinical Endocrinology & Metabolism”

Leuprolide effectively reduces hair growth in hirsute women at higher doses.

research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer

2 citations , December 2013 in “Cancer research”

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Sequential Estrogen-Progestin Addition to Gonadotropin-Releasing Hormone Agonist Suppression for the Chronic Treatment of Ovarian Hyperandrogenism: A Pilot Study

research Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.

2 citations , December 1994 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

research Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH

21 citations , April 2016 in “International Journal of Oncology”

GnRH treatment can reduce breast cancer cell invasion.

research Sertoli–Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism

5 citations , October 2014 in “Gynecological Endocrinology”

Triptorelin helps evaluate hormone production in Sertoli-Leydig cell tumors.

research The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty

34 citations , May 1987 in “European Journal of Pediatrics”

Buserelin safely and effectively suppresses early puberty, potentially improving final height.

research Long-Term Suppression of Testosterone After Treatment with a Gonadotropin-Releasing Hormone Agonist in a Woman with a Presumed Testosterone Secreting Ovarian Tumor

19 citations , June 1997 in “The Journal of Clinical Endocrinology & Metabolism”

The treatment successfully lowered testosterone levels and reduced symptoms.

research Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients

57 citations , December 2018 in “JAMA Surgery”

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.

research Successful deslorelin implant treatment in a neutered female Pomeranian dog with Alopecia X

January 2025 in “Brazilian Journal of Veterinary Medicine/Revista Brasileira de Medicina Veterinária”

Deslorelin implant successfully regrew hair in a female Pomeranian with alopecia X.

research REAL WORLD STUDY ON ORAL ESTRADIOL TREATMENT IN TRANSGENDER WOMEN

October 2022 in “Journal of the ASEAN Federation of Endocrine Societies”

GnRH-a or orchiectomy is more effective than anti-androgens for managing hormone levels in transgender women.

research Dienogest versus gonadotropin-releasing hormone analogues for the clinical treatment of endometriosis: an updated meta-analysis

November 2024 in “International Journal of Scientific Reports”

Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.

research Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy

19 citations , March 1994 in “Fertility and sterility”

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate

52 citations , July 1998 in “Urology”

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

research Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain

July 2025 in “Annals of Medicine”

Gestrinone pellets may help reduce pelvic pain in endometriosis safely.

research Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients

116 citations , May 1992 in “The American Journal of Medicine”

Flutamide rarely causes liver toxicity in prostate cancer patients.

A Randomized Phase II Trial on the Addition of Dutasteride to Combined Androgen Blockade Therapy Versus Combined Androgen Blockade Therapy Alone in Patients with Advanced or Metastatic Salivary Duct Carcinoma – The DUCT Study Protocol

research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol

4 citations , September 2024 in “BMC Cancer”

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

research Absence of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism: case report

3 citations , October 2003 in “Annals of Oncology”

A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.

Androgenic Effects on Ventricular Repolarization: A Translational Study from Pharmacovigilance Databases to iPSC-Cardiomyocytes

research P6590Androgenic effects on ventricular repolarization: a translational study from pharmacovigilance databases to iPSC-cardiomyocytes

October 2019 in “European heart journal”

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

research [Clinical findings with a low-dosed antiandrogene (cyproteronacetate) and aethinyloestradiol women with virilising symptoms (author's transl)].

3 citations , April 1977 in “PubMed”

The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.

research Deslorelin treatment of hyperoestrogenism in neutered ferrets (Mustela putorius furo): a case report

6 citations , February 2009 in “Veterinární Medicína”

Deslorelin effectively treats hair loss in neutered ferrets by reducing hormone levels.